Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication
Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...
AstraZeneca: IMFINZI improved event-free survival, OS across MIBC
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, administered ...
Armed robbery in Revesby15h
Wildlife Habitat Restoration in Rich Nations May Harm Biodiversity
Researchers call on the international community to recognise and start tackling the "biodiversity leak". Areas of much greater ...
Vistagen advances Phase 3 SAD trials with 2025 data readout target
Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...
AstraZeneca's Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients
AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority ...
rheumatologyadvisor9h
Low-Dose Methotrexate Shows Minimal Impact on Blood Pressure
Low-dose methotrexate was not clinically effective for lowering blood pressure among patients without rheumatic disease who have cardiovascular risk factors.